Procept Biorobotics Corporation has announced the successful completion of three prostate cancer procedures as part of the WATER IV Prostate Cancer (PCa) Trial at an Ambulatory Surgery Center using Aquablation® therapy. Conducted by Dr. Rahul Mehan of East Valley Urology in Scottsdale, Arizona, the procedures were completed without complications, allowing for same-day patient discharge. The WATER IV PCa trial is a U.S. FDA investigational device exemption $(IDE)$ approved study comparing the safety and efficacy of Aquablation therapy and radical prostatectomy in treating localized prostate cancer. The trial aims to evaluate a minimally invasive approach that utilizes a robotically-controlled waterjet for tissue resection. Results of the trial are anticipated to be presented in the future.